Tzield

News

FDA delays decision on Sanofi's subcutaneous Sarclisa

The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.

News

Texas sues Sanofi, claiming kickbacks to doctors

Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines.

News

Call goes out for type 1 diabetes screening in UK

A finger-prick screening programme for type 1 diabetes should roll out in the UK, say researchers, given a disease-modifying drug is now available.

News

Sanofi seeks use of type 1 diabetes drug in younger kids

Sanofi could be months away from wider US approval for Tzield, its drug for delaying the progression of type 1 diabetes, in children as young as one.

News

Sanofi buys Provention and diabetes drug Tzield for $2.9bn

T1D prevention drug has been tipped as a blockbuster, boosting Sanofi's diabetes franchise.

News

Provention prices type 1 diabetes drug Tzield at $194,000

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been pr

FDA delays decision on Sanofi's subcutaneous Sarclisa

Texas sues Sanofi, claiming kickbacks to doctors

Call goes out for type 1 diabetes screening in UK

Sanofi seeks use of type 1 diabetes drug in younger kids

Sanofi buys Provention and diabetes drug Tzield for $2.9bn

Provention prices type 1 diabetes drug Tzield at $194,000

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Tzield

Editor's Picks